WO2008007914A1 - Séquence nucléotidique d'un argf mutant présentant une activité plus importante et procédé de production de l-arginine au moyen d'une cellule transformée contenant la séquence nucléotidique - Google Patents

Séquence nucléotidique d'un argf mutant présentant une activité plus importante et procédé de production de l-arginine au moyen d'une cellule transformée contenant la séquence nucléotidique Download PDF

Info

Publication number
WO2008007914A1
WO2008007914A1 PCT/KR2007/003391 KR2007003391W WO2008007914A1 WO 2008007914 A1 WO2008007914 A1 WO 2008007914A1 KR 2007003391 W KR2007003391 W KR 2007003391W WO 2008007914 A1 WO2008007914 A1 WO 2008007914A1
Authority
WO
WIPO (PCT)
Prior art keywords
arginine
argf
producing
gene
strain
Prior art date
Application number
PCT/KR2007/003391
Other languages
English (en)
Inventor
Young Hoon Park
Hye Won Kim
Ji-Hye Lee
Soo-Youn Hwang
Original Assignee
Cj Cheiljedang Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cj Cheiljedang Corporation filed Critical Cj Cheiljedang Corporation
Publication of WO2008007914A1 publication Critical patent/WO2008007914A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/10—Citrulline; Arginine; Ornithine

Definitions

  • a NUCLEOTIDE SEQUENCE OF A MUTANT ARGF WITH INCREASED ACTIVITY AND A METHOD FOR PRODUCING L-ARGININE USING A TRANSFORMED CELL CONTAINING
  • the present invention relates to a nucleotide sequence of a mutant argF gene, which is involved in arginine biosynthesis. More particularly, the present invention relates to a nucleotide sequence of a mutant argF gene, which has a partial nucleotide sequence varied and thus results in an amino acid sequence varied from the wild type sequence, so as to increase ornithine carbamoyltransferase activity, a recombinant vector carrying the nucleotide sequence, and a cell transformed with the recombinant vector. Also, the present invention is concerned with a method of producing high levels of L-arginine by culturing the transformant.
  • L-arginine a semi-essential amino acid that is naturally produced in the body, has been widely used in medicaments, food, animal feedstuffs, and other products.
  • L- arginine is useful as a drug for improving hepatic function and brain function and treating male sterility and as an ingredient of multiple amino acid supplements.
  • L-arginine has been used as a food additive in fish cakes and health beverages, and has recently gained interest as a salt substitute for hypertension patients.
  • L-arginine can be produced using a mutant strain derived from a glutamate- producing microorganism belonging to the genus Brevibacterium or Corynebacterium (Japanese Pat. Laid-Open Publication Nos. Sho57-163487, Sho ⁇ O-83593 and Sho62-265988), or using an amino acid-producing microorganism having improved growth properties by cell fusion (Japanese Pat. Laid-Open Publication No. Sho59-158185).
  • L-arginine In microorganisms, the biosynthesis of L-arginine proceeds in eight enzymatic steps starting from L-glutamate through two different pathways, the linear pathway or the cyclic pathway. In the linear pathway, L-arginine is synthesized from L-glutamate via N-acetylglutamate, N-acetylornithine, ornithine, citralline and argininosuccinate.
  • These intermediates are synthesized through consecutive reactions catalyzed by the following enzymes, N-acetylglutamate synthase, N-acetylglutamate kinase, N- acetylglutamylphosphate reductase, acetylornithine aminotransferase, acetylornithine deacetylase, ornithine carbamoyltransferase, argininosuccinate synthase and argini- nosuccinase.
  • These enzymes are encoded by argA, argB, argC, argD, argE, argF, argG and argH genes, respectively.
  • L-arginine in higher yields intended to amplify the argF gene encoding ornithine carbamoyltransferase, which catalyzes the conversion of ornithine into citrulline in the arginine biosynthetic pathway, and then to achieve the improved productivity of L- arginine using a mutant argF gene, which allows enhancement of the gene-encoded enzyme activity compared to the wild type, thereby leading to the present invention.
  • the expression of the argF gene is controlled by the repressor protein argR and intracellular arginine.
  • the argR protein negatively regulates the expression of the argF gene (Dongbin Lim, Werner K. Mass, 1987, PNAS 84: 6697-6701).
  • the activity of the argF protein has been reported to be suppressed by the presence of high concentrations of arginine (Raymon Cunin, Victor Stalon, 1986, Microbiological Reviews 50: 314-352).
  • the inactivation of the argR gene increases the expression of the argF gene and enhances the production efficiency of arginine (U.S. Pat. Application No.
  • the present inventors have constructed an expression vector that comprises the argF gene obtained from a mutant strain that produces arginine in high levels using a genetic engineering technique, and have introduced the expression vector into an arginine-producing strain, thereby developing a strain capable of producing high concentrations of L-arginine.
  • the strain was substantially used in fermentation for arginine production, the yield of L-arginine remarkably increased.
  • the present invention aims to provide a recombinant microorganism producing the amino acid L-arginine in higher yields and a preparation method thereof comprising preparing a modified argF gene or a DNA fragment thereof, constructing a vector capable of expressing the mutant argF gene in C. glutamicum, and introducing the vector into an L-arginine-producing strain.
  • the present inventors have constructed an expression vector that comprises the argF gene obtained from a mutant strain that produces arginine at high levels using a genetic engineering technique, and have introduced the expression vector into an arginine- producing strain, thereby developing a strain capable of producing high concentrations of L-arginine.
  • the strain was substantially used in fermentation for arginine production, the yield of L-arginine remarkably increased.
  • the L-arginine-producing microorganism overexpressing the argF gene according to the present invention increases the yield of L-arginine.
  • FIG. 1 shows a process for constructing a recombinant plasmid pECCGl 17-argF according to the present invention.
  • the present invention is characterized by targeting the argF gene, encoding ornithine carbamoyltransferase, in order to improve the productivity of L-arginine.
  • the present invention involves obtaining the argF gene from an L- arginine-producing microorganism, inserting the argF gene into a vector in order to construct an argF expression vector and introducing the expression vector into an L- arginine-producing strain using a genetic engineering technique, thereby increasing the productivity of L-arginine even in the presence of high concentrations of arginine during fermentation.
  • This concept of the present invention is applicable to all microorganisms, including prokaryotes and eukaryotes, that are able to produce L-arginine.
  • Representative microorganisms may include E. coli, coryneform bacteria, and Bacillus bacteria, which have been conventionally used to produce L-arginine.
  • Preferred is a strain of Corynebacterium glutamicum, which is resistant to an L-arginine analogue and is capable of producing L-arginine.
  • the expression of the argF gene, located on a chromosome of a microorganism producing L-arginine, may be achieved using a common genetic engineering technique.
  • the nucleotide sequence of the gene may be analyzed using a fluorescent DNA sequencing method.
  • the gene expression vector of the present invention is constructed according to the following procedure.
  • the genomic DNA is isolated from a microbial strain capable of producing L-arginine.
  • a polymerase chain reaction (PCR) is performed using the isolated genomic DNA as a template in accordance with the standard protocols in order to amplify the ORF of the argF gene, the argC promoter region and the rrnB terminator region.
  • the nucleotide sequence of the argF gene thus obtained is determined using a common DNA sequencing method.
  • the amplified promoter, argF gene and terminator are sequentially cloned into a suitable plasmid or vector.
  • the resulting recombinant vector or plasmid is transformed into a host cell, such as E.
  • the transformant is cultivated to be propagated, and the recombinant vector, carrying, sequentially, the promoter, argF gene and terminator, is extracted from the culture.
  • the extracted recombinant vector is introduced into a microbial strain capable of producing L-arginine using a common technique, such as electroporation.
  • a strain harboring the recombinant vector is then selected using its antibiotic resistance.
  • nucleotide sequence analysis and DNA fragment preparation of the present invention can be performed using standard DNA sequencing and cloning methods.
  • PCR is preferably carried out using oligonucleotide primers targeting the argC promoter, argF gene and rrnB terminator according to the present invention.
  • the PCR method is well known in the art (see, PCR Protocols: A Guide to Method and Application, Ed. M. Innis et al., Academic Press (1990)).
  • the PCR is performed in a PCR mixture containing genomic DNA, an appropriate polymerase, primers and buffer conveniently using a PTC-200 Peltier Thermal Cycler (MJ Research, USA). Positive PCR results are determined, for example, by detecting a suitable size of a DNA fragment through electrophoresis on an agarose gel.
  • the mutant strain capable of producing L-arginine has a resistance to an L-arginine analogue.
  • the L-arginine analogue includes canavanine and arginine hydroxamate.
  • the present inventors constructed a recombinant plasmid pECCGl 17-argF, and introduced the recombinant plasmid into C. glutamicum CJR0500, having resistance to an L-arginine analogue using electroporation, thereby developing a novel strain that overexpresses the mutant argF gene and thus produces higher concentrations of L-arginine compared to the parent strain.
  • the present applicant deposited the novel mutant strain of Corynebacterium, CJR0586, at the Korean Culture Center of Microorganisms (KCCM) on March 15, 2006 so as to make it available to those skilled in the art, and the deposit was assigned accession number KCCM- 10742P.
  • the novel mutant strain CJR0586 of the present invention is derived from the parent strain CJR0500, which is induced from a glutamine-producing strain KFCC- 10680 (Korean Pat. Publication No. 91-7818).
  • the parent strain CJR0500 is a mutant strain, which is induced by treating Corynebacterium glutamicum KFCC- 10680 with N-methyl-N-nitro-N-nitrosoguanidine (NTG), as a general method for mutagenesis, smearing said treated C.
  • glutamicum KFCC- 10680 onto a minimal medium (1.0% glucose, 0.4% ammonium sulfate, 0.04% magnesium sulfate, 0.1% potassium phosphate monobasic, 0.1% urea, 0.0001% thiamine, 200 ⁇ g/L biotin, 2% agar, pH 7.0) supplemented with canavanine and arginine hydroxamate, and selecting a clone resistant to 500 mg/L of each of canavanine and arginine hydroxamate.
  • the genomic DNA was isolated from the L-arginine-producing strain CJR0500 using a QIAGEN Genomic-tip system. PCR was carried out using the genomic DNA as a template in order to amplify the argC promoter region and the open reading frame (ORF) of the argF gene, thereby obtaining two DNA fragments (362 bp and 1059 bp, respectively). In order to fuse the argC promoter region to the argF gene, another PCR was carried out using the two amplified DNA fragments for the argC promoter and the argF gene as a template, thereby obtaining a fused fragment of 1421 bp.
  • ORF open reading frame
  • the argC promoter region was amplified using a pair of primers: 5'- cgcggatccggctacttcc- gaggaatcttc-3' (SEQ ID No. 3) and 5'-acaccatacacgttatgcatga-3' (SEQ ID No. 4), and PCR conditions included 20 cycles of denaturation at 94 0 C for 30 sec, annealing at 55 0 C for 30 sec and extension at 72 0 C for 30 sec.
  • the resulting PCR reaction mixture was electrophoresed on a 1.0% agarose gel, and a band of 0.4 kb was excised from the gel.
  • PCR conditions included 20 cycles of denaturation at 94 0 C for 30 sec, annealing at 55 0 C for 30 sec and extension at 72 0 C for 1 min.
  • the resulting PCR reaction mixture was electrophoresed on a 0.8% agarose gel, and a band of 1 kb was excised from the gel.
  • PCR for obtaining the fused fragment of the argC promoter and the argF gene was performed using a pair of primers: 5'-cgcggatccggctacttccgaggaatcttc-3' (SEQ ID No. 3) and 5'-acgcgatatccatgtcttacctcggctggt-3' (SEQ ID No. 6).
  • PCR conditions included 20 cycles of denaturation at 94 0 C for 30 sec, annealing at 55 0 C for 30 sec and extension at 72 0 C for 1 min 30 sec.
  • the resulting PCR reaction mixture was electrophoresed on a 0.8% agarose gel, and a band of 1.4 kb was excised from the gel.
  • the rrnB terminator was amplified using pKK233 as a template DNA with a pair of primers: 5'-acgcgatatcctgttttggcggatgagaga-3' (SEQ ID No. 7) and 5'-cggggtacccaaaaaggccatccgtcag-3' (SEQ ID No. 8).
  • PCR conditions included 30 cycles of denaturation at 94 0 C for 30 sec, annealing at 55 0 C for 30 sec and extension at 72 0 C for 30 sec.
  • the resulting PCR reaction mixture was electrophoresed on a 1.0% agarose gel, and a band of 0.4 kb was excised from the gel.
  • a plasmid pECCGl 17 was digested with BamHI and Kpnl, and a band of about 5.9 kb was excised from a 0.8% agarose gel.
  • the fusion PCR product of the argC promoter and the argF gene was digested with BamHI and EcoRV, and a band of about 1.4 kb was excised from a 0.8% agarose gel.
  • the PCR product for the rrnB terminator was digested with EcoRV and Kpnl, and a band of about 0.4 kb was excised from a 1% agarose gel.
  • the three DNA fragments were ligated and inserted into the linearized pECCGl 17 plasmid, thereby obtaining a recombinant plasmid pECCGl 17-argF (about 7.7 kb) (FIG. 1).
  • the recombinant plasmid pECCGl 17-argF was introduced into an L- arginine-producing strain (CJR0500) using electroporation, and was smeared onto a solid medium containing kanamycin. The emerged colonies were subjected to an arginine productivity test in a flask.
  • L-arginine seed medium 5% glucose, 1% bactopeptone, 0.25% sodium chloride, 1% yeast extract, 3 ⁇ g/L biotin, 0.4% urea, pH 7.0
  • the cells were cultured in the seed medium in an incubator at 3O 0 C for 16 hrs. 1 ml of the seed culture was inoculated in 24 ml of the medium for L-arginine productivity assay, and culturing was carried out at 3O 0 C for 72 hrs with agitation at 250 rpm.
  • the results for L-arginine productivity are given in Table 1, below.
  • the parent strain CJR0500 exhibited L-arginine productivity of 2.8 g/L.
  • the recombinant strain CJR0586, overexpressing the argF gene displayed a higher arginine productivity of 3.1 g/L, which was increased by about 10% compared to the parent strain.
  • EXAMPLE 3 Determination of the nucleotide sequence of the mutant argF gene
  • nucleotide sequence of the recombinant vector pECCGl 16-argF was analyzed.
  • a PCR was carried out using 0.1 ⁇ g of pECCGl 16-argF as a template with 2 mM of a pair of primers of SEQ ID Nos. 3 and 6 and 1 ⁇ l of a BigDyeTM Terminator Cycle Sequencing v2.0 Ready Reaction (PE Biosystems).
  • PCR conditions included 30 cycles of denaturation at 95 0 C for 30 sec, annealing at 55 0 C for 30 sec and extension at 72 0 C for 1 min 30 sec, followed by quenching at 4 0 C.
  • a DNA fragment of 1.4 kb was then isolated. This DNA fragment was subjected to sequencing analysis using the primer of SEQ ID No. 3, and sequencing was performed on an ABI PRISM 3100 Genetic AnalyzerTM (Applied Biosystems).
  • Sequencing analysis identified eight base substitutions in argF, the structural gene for ArgF protein.
  • the base substitutions resulted in a substitution of threonine (T) for a serine (S) residue at position 88 in the ArgF protein.
  • T threonine
  • S serine
  • the determined nucleotide sequence of the mutant argF gene and the amino acid sequence having the aforementioned substitution are shown in SEQ ID Nos. 1 and 2, respectively.
  • the L-arginine-producing microorganism overexpressing the argF gene according to the present invention increases the yield of L-arginine.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Cette invention concerne une molécule d'acide nucléique d'un gène argF mutant, laquelle eset impliquée dans la biosynthèse de l'arginine. Le produit protéique du gène argF mutant, dans lequel une séquence nucléotidique partielle ou une séquence d'acides aminés est substituée, présente une activité ornithine carbamoyltransférase plus importante. En outre, cette invention concerne un vecteur de recombinaison contenant une molécule d'acides nucléiques et une cellule transformée avec le vecteur de recombinaison. En outre, cette invention concerne un procédé permettant de produire des niveaux élevés de L-arginine en cultivant le transformant. Le micro-organisme de recombinaison permet d'obtenir une meilleure production de L-arginine.
PCT/KR2007/003391 2006-07-13 2007-07-12 Séquence nucléotidique d'un argf mutant présentant une activité plus importante et procédé de production de l-arginine au moyen d'une cellule transformée contenant la séquence nucléotidique WO2008007914A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020060065989A KR100854234B1 (ko) 2006-07-13 2006-07-13 역가가 향상된 유전자 ａｒｇＦ 염기서열 및 그를 포함하는형질전환 균주를 이용한 Ｌ―알지닌의 생산방법
KR10-2006-0065989 2006-07-13

Publications (1)

Publication Number Publication Date
WO2008007914A1 true WO2008007914A1 (fr) 2008-01-17

Family

ID=38923432

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2007/003391 WO2008007914A1 (fr) 2006-07-13 2007-07-12 Séquence nucléotidique d'un argf mutant présentant une activité plus importante et procédé de production de l-arginine au moyen d'une cellule transformée contenant la séquence nucléotidique

Country Status (2)

Country Link
KR (1) KR100854234B1 (fr)
WO (1) WO2008007914A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017518760A (ja) * 2014-10-13 2017-07-13 シージェイ チェイルジェダング コーポレイション Ｌ−アルギニンを生産するコリネバクテリウム属の微生物及びそれを用いたｌ−アルギニンの製造方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016060437A1 (fr) * 2014-10-13 2016-04-21 씨제이제일제당 주식회사 Micro-organisme du genre corynebacterium pour la production de l-arginine, et procédé de production de l-arginine l'utilisant
KR102269637B1 (ko) * 2018-12-26 2021-06-28 대상 주식회사 L-시트룰린 또는 l-아르기닌 생산능이 향상된 변이 균주 및 이를 이용한 l-시트룰린 또는 l-아르기닌의 제조 방법
KR20240013960A (ko) * 2022-07-21 2024-01-31 대상 주식회사 L-아르기닌 또는 l-시트룰린 생산능이 향상된 코리네박테리움 속 미생물 및 이를 이용한 l-아르기닌 또는 l-시트룰린의 생산 방법
KR20240013961A (ko) * 2022-07-21 2024-01-31 대상 주식회사 L-아르기닌 또는 l-시트룰린 생산능이 향상된 코리네박테리움 속 미생물 및 이를 이용한 l-아르기닌 또는 l-시트룰린의 생산 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020045223A1 (en) * 2000-04-28 2002-04-18 Ajinomoto Co., Inc. Arginine repressor deficient strain of coryneform bacterium and method for producing L-arginine
EP1460128A1 (fr) * 2003-03-03 2004-09-22 Ajinmoto Co., Inc. Procédé de production de L-Arginine ou L-Lysine par fermentation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020045223A1 (en) * 2000-04-28 2002-04-18 Ajinomoto Co., Inc. Arginine repressor deficient strain of coryneform bacterium and method for producing L-arginine
EP1460128A1 (fr) * 2003-03-03 2004-09-22 Ajinmoto Co., Inc. Procédé de production de L-Arginine ou L-Lysine par fermentation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHUN J.Y. ET AL.: "Cloning of the argF gene encoding the ornithine carbamoyltransferase form Corynebacterium glutamicum", MOL. CELLS, vol. 9, no. 3, 30 June 1999 (1999-06-30), pages 333 - 337 *
DATABASE GENBANK [online] Database accession no. (AF031518) *
DATABASE GENBANK [online] Database accession no. (AF049897) *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017518760A (ja) * 2014-10-13 2017-07-13 シージェイ チェイルジェダング コーポレイション Ｌ−アルギニンを生産するコリネバクテリウム属の微生物及びそれを用いたｌ−アルギニンの製造方法
US10626426B2 (en) 2014-10-13 2020-04-21 Cj Cheiljedang Corporation Microorganism of genus Corynebacterium having an ability to produce L-arginine and a method for producing L-arginine using the same

Also Published As

Publication number Publication date
KR20080006799A (ko) 2008-01-17
KR100854234B1 (ko) 2008-08-25

Similar Documents

Publication Publication Date Title
US20230072150A1 (en) Microorganism comprising variant lyse and method of l-amino acid production using same
JP4638048B2 (ja) Ｌ−バリンを微生物により製造する方法
JP4881739B2 (ja) Ｌ−アルギニン、ｌ−オルニチンまたはｌ−シトルリンの製造法
KR102137806B1 (ko) 글라이신 생산능이 증가된 미생물 및 이를 이용한 발효 조성물 생산 방법
EP2102347B9 (fr) Variété de corynebactérium glutamicum produisant de la l-arginine et son procédé de fabrication
TWI738050B (zh) 變體磷酸核糖焦磷酸胺基轉移酶及使用該轉移酶製備嘌呤核苷酸的方法
RU2681475C1 (ru) Вариант репрессора глюконата, микроорганизм-продуцент L-лизина, содержащий его, и способ получения L-лизина с его использованием
WO2008007914A1 (fr) Séquence nucléotidique d'un argf mutant présentant une activité plus importante et procédé de production de l-arginine au moyen d'une cellule transformée contenant la séquence nucléotidique
EP3106516A1 (fr) Micro-organisme de recombinaison de genre escherichia à productivité de l-thréonine et procédé de production l-thréonine l'utilisant
US20240167065A1 (en) Microorganism having increased activity of 3-methyl-2-oxobutanoate hydroxymethyltransferase, and use thereof
WO2014027702A1 (fr) Procédé de production de l-arginine à l'aide d'une bactérie de la famille des entérobactériacées présentant une n-acétylornithine désacétylase dotée d'une activité réduite
KR100830290B1 (ko) Ｌ－아르기닌 생산 변이주 및 이의 제조방법
KR101687474B1 (ko) L-아르기닌 생산능이 향상된 코리네박테리움속 미생물 및 이를 이용한 l-아르기닌의 생산 방법
EP2837688A1 (fr) Procédé de production d'un acide aminé
CN116555152B (zh) 大肠杆菌及其构建方法与在生产l-缬氨酸中的应用
CN116555151B (zh) 产l-缬氨酸工程菌及构建方法与应用
US20220275412A1 (en) Microorganism for producing l-amino acid having increased cytochrome c activity, and l-amino acid production method using same
JP2024515389A (ja) Ｌ－リシン生産能が向上したコリネバクテリウム・グルタミカム変異株及びそれを用いたｌ－リシンの生産方法
CN116334112A (zh) 氨基酸生产菌株的构建方法及其应用
CN116555155A (zh) 用于生产l-缬氨酸的大肠杆菌及其构建方法与应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07768722

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07768722

Country of ref document: EP

Kind code of ref document: A1